Dissociable effects of dopaminergic medications on depression symptom dimensions in Parkinson disease
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Dissociable effects of dopaminergic medications on depression symptom dimensions in Parkinson disease ; volume:2 ; number:8 ; day:17 ; month:6 ; year:2024 ; pages:916-923 ; date:8.2024
Nature Mental Health ; 2, Heft 8 (17.6.2024), 916-923, 8.2024
- Urheber
-
Costello, Harry
Schrag, Anette-Eleonore
Howard, Robert
Roiser, Jonathan P.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s44220-024-00256-8
- URN
-
urn:nbn:de:101:1-2410272115363.053537546141
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Costello, Harry
- Schrag, Anette-Eleonore
- Howard, Robert
- Roiser, Jonathan P.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Speech Characteristics of Patients with Parkinson's Disease—Does Dopaminergic Medications Have a Role?
Erratum: Speech Characteristics of Patients with Parkinson's Disease–Does Dopaminergic Medications Have a Role?
Parkinson’s Disease, the Dopaminergic Neuron and Gammahydroxybutyrate
Dopaminergic neuron metabolism: relevance for understanding Parkinson’s disease
Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson’s disease: evidence for dopaminergic basis?
Neuromelanin Imaging and Dopaminergic Loss in Parkinson's Disease
Identifying potential repurposable medications for Parkinson’s disease through Mendelian randomization analysis
Depression, antidepressant medications, and risk of Clostridium difficileinfection
Depression und Parkinson-Krankheit
Motivational modulation of bradykinesia in Parkinson’s disease off and on dopaminergic medication
Clinical characteristics of fatigued Parkinson’s patients and the response to dopaminergic treatment
Loss of Drosha underlies dopaminergic neuron toxicity in models of Parkinson’s disease
Speech Characteristics of Patients with Parkinson's Disease—Does Dopaminergic Medications Have a Role?
Erratum: Speech Characteristics of Patients with Parkinson's Disease–Does Dopaminergic Medications Have a Role?
Parkinson’s Disease, the Dopaminergic Neuron and Gammahydroxybutyrate
Dopaminergic neuron metabolism: relevance for understanding Parkinson’s disease
Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson’s disease: evidence for dopaminergic basis?
Neuromelanin Imaging and Dopaminergic Loss in Parkinson's Disease
Identifying potential repurposable medications for Parkinson’s disease through Mendelian randomization analysis
Depression, antidepressant medications, and risk of Clostridium difficileinfection
Depression und Parkinson-Krankheit
Motivational modulation of bradykinesia in Parkinson’s disease off and on dopaminergic medication
Clinical characteristics of fatigued Parkinson’s patients and the response to dopaminergic treatment
Loss of Drosha underlies dopaminergic neuron toxicity in models of Parkinson’s disease
Speech Characteristics of Patients with Parkinson's Disease—Does Dopaminergic Medications Have a Role?
Erratum: Speech Characteristics of Patients with Parkinson's Disease–Does Dopaminergic Medications Have a Role?
Parkinson’s Disease, the Dopaminergic Neuron and Gammahydroxybutyrate
Dopaminergic neuron metabolism: relevance for understanding Parkinson’s disease
Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson’s disease: evidence for dopaminergic basis?
Neuromelanin Imaging and Dopaminergic Loss in Parkinson's Disease
Identifying potential repurposable medications for Parkinson’s disease through Mendelian randomization analysis
Depression, antidepressant medications, and risk of Clostridium difficileinfection
Depression und Parkinson-Krankheit
Motivational modulation of bradykinesia in Parkinson’s disease off and on dopaminergic medication
Clinical characteristics of fatigued Parkinson’s patients and the response to dopaminergic treatment